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Accepted 14 November 2018Objective: To describe fetomaternal hemorrhage (FMH) during second-trimester dilation and evacuation (D&E)
to evaluate if Rhesus-immune globulin (RhIG) 100 mcg (used in the United Kingdom) and 300 mcg (used in
the United States) provide adequate prophylaxis.
Study design:We conducted an exploratory prospective descriptive study of women undergoing D&E between
15 weeks 0 days and 23 weeks 6 days of gestation. Enrolled participants had Kleihauer–Betke testing on speci-
mens obtained before and after D&E. We assessed the main outcome measures of FMH in mL suggesting need
for more than 100 mcg and 300 mcg RhIG (FMH of 10 mL and 30 mL fetal whole blood, respectively) and asso-
ciation of postprocedure FMH with demographic characteristics and procedure-related variables.
Results: The 300 participants had a mean gestational age of 19 weeks 6 days±2 weeks 2 days. The median
preprocedure FMH was 0 mL (range 0–50 mL) with 2 (0.67%) women exceeding 10 mL (19 mL and 50 mL).
The median postprocedure FMH was 1 mL (range 0–60 mL). Almost all participants had postprocedure FMH
b10 mL (n=295, 98.3%) and b30 mL (n=298, 99.3%). All participants under 18 weeks had FMH b10 mL. We
found no demographic or procedure-related factors to be predictive of FMH quantity.
Conclusions: FMH occurring with routine second-trimester D&E procedures is minimal. Adequate prophylaxis
with RhIG 100 mcg and 300 mcg occurred in N98% of women and in all cases b18 weeks of gestation. This
study is the ﬁrst step to potentially reducing the dose and costs of RhIG administration with D&E.
Implications: This study is a ﬁrst step in quantifying fetomaternal hemorrhage with routine dilation and evacua-
tion procedures; larger trials are needed, especially to understand why some women have recognizable hemor-
rhage preprocedure. If dosing requirements are too high with current guidelines, lower doses will result in
resource and cost savings.
© 2018 Published by Elsevier Inc.Keywords:
Dilation and evacuation
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Rh immune globulin
Rh prophylaxis1. Introduction
Fetomaternal hemorrhage (FMH) occurs when fetal cells enter the
maternal circulation during events such as amniocentesis, trauma, abor-
tion procedures and delivery and can lead to immune sensitization in
Rhesus (Rh)-negativewomen. Standard care includes Rh-immune glob-
ulin (IG) administration to unsensitized Rh-negative women to prevent
maternal isoimmunization during any potentially sensitizing event or
when FMH is suspected.).
rics and Gynecology, Palo Alto
of Obstetrics and Gynecology,RhIG is crucial in prevention of isoimmunization and possible fetal
morbidity in subsequent pregnancies, with timely administration
preventing 80%–90% of isoimmunization [1,2]. Since the 1970s, countries
with Rh-prophylaxis guidelines have seen signiﬁcant decreases in
isoimmunization and hemolytic disease of the fetus and newborn. How-
ever, guidelines from various national societies differ in recommended
dosing and timing of administration during pregnancy and other poten-
tially sensitizing events [3]. Notably, UK second-trimester guidelines rec-
ommendRhIG50mcg for any potentially sensitizing event until 20weeks
of gestation and RhIG 100mcg thereafter in conjunctionwith FMH quan-
tiﬁcation [4]. Conversely, US guidelines recommend a 300-mcg dosewith
any potentially sensitizing event at 12 or more weeks of gestation [1].
These variable RhIG doses correlate with FMH of fetal whole blood into
the maternal circulation of 5 mL, 10 mL and 30 mL for RhIG 50 mcg,
100 mcg and 300 mcg, respectively. Despite the discrepancy, initial stud-
ies dating back to the 1970s indicate that both the UK and US dosing
Table 1
Demographic, obstetric and hematologic characteristics of women having abortion who
had pre- and postprocedure Kleihauer–Betke testing (N=300)
Characteristic n (%) or mean ± SD Range
Age (years) 27.1±6.7 14–44
BMI (kg/m2) 28.7±6.9 14.7–58.7
Gestational age (days) 139.1±16.1 105–167
Non-Hispanic ethnicity 212 (70.1)
Race
White 163 (54.3)
Black 70 (23.3)
Asian 18 (6.0)
Other 49 (16.3)
Gravidity 1–15
1 66 (22.0)
2 39 (13.0)
3 52 (17.3)
4 44 (14.7)
5–6 55 (18.3)
7 or more 44 (14.7)
Prior vaginal delivery 0–7
0 131 (43.7)
1 61 (20.3)
2 64 (21.3)
3 or more 44 (14.7)
Prior cesarean delivery 0–4
0 229 (76.3)
1 41 (13.7)
2 17 (5.7)
3 or more 13 (4.3)
Prior spontaneous abortion 76 (25.3) 0–4
Prior induced abortion 146 (48.7) 0–6
Suspected morbidly adherent placenta 16 (5.3)
Fetal anomaly indication for abortion 39 (13.0)
Blood type
A 102 (34.0)
AB 5 (1.7)
B 41 (13.7)
O 152 (50.7)
Rhesus-negative 27 (9.0)
282 J.K. Hsia et al. / Contraception 99 (2019) 281–284regimens similarly decrease isoimmunization and hemolytic disease of
the fetus and newborn [1,5].
The only available second-trimester FMH data primarily include in-
duction abortions for fetal anomalies [6,7], and no studies speciﬁcally
evaluate FMH with dilation and evacuation (D&E). Given recent RhIG
shortages around the world such as in Australia and Poland [8,9], and
the cost of higher doses of RhIG to healthcare systems, we sought to
begin to understand if a RhIG dose less than 300mcgmight be sufﬁcient
in the second trimester. We designed this study to evaluate FMH with
routine D&E from 15 weeks 0 days to 23 weeks 6 days of gestation
using Kleihauer–Betke (KB) acid elution testing.
2. Materials and methods
From February 2016 to April 2017, we approached patients in our
outpatient clinic for possible study participation during a preoperative
evaluation with planned cervical osmotic dilator placement to be
followed the next day by D&E. We included women with a singleton
pregnancy whowould be 15 weeks 0 days to 23 weeks 6 days of gesta-
tion on the day of their procedure based on the clinical preoperative
evaluation using standard obstetrical dating and abdominal ultrasound
examination. We excluded women with a fetal demise, incarcerated
women and women unable to consent for themselves. The University
of California, Davis, Institutional Review Board approved the study,
and all subjects signed written informed consent after signing consent
for the abortion and prior to cervical preparation.
We used Dilapan-S® (MEDICEM Technology, s.r.o., Czech Republic)
synthetic osmotic dilators for cervical preparation based on a standardized
gestational-age-based protocol for all providers (Online Appendix 1).
Providers could also use adjunctive mifepristone 200 mg orally or miso-
prostol 400 mcg vaginally per their clinical judgment.
We obtained preprocedure blood samples at the time of intravenous
line placement in the preoperative area prior to the D&E. We deﬁned
the procedure start as the time the ﬁrst instrument passed into the
uterus (rigid dilators, suction cannula or forceps) and end as the time
the last instrument related to the D&E procedure was removed from
the uterus. If postprocedure intrauterine device placement occurred,
that time was not included in total procedure time. One of ﬁve
fellowship-trained Family Planning attending physicians performed or
supervised fellows, residents or medical students for each case.
We obtained a postprocedure blood sample between 30 and
120 min after the procedure ended. Rh-negative participants received
RhIG 300 mcg after obtaining the postprocedure blood sample. We
withdrew enrolled participants for whom a postprocedure blood sam-
ple could not be obtained after three attempts or those who required
additional postoperative procedures for hemorrhage, including intra-
uterine balloon placement or blood transfusion.
Wemeasured FMHusingKB acid elution testing. To limit interreader
variability, one of three hematology senior clinical laboratory scientists
devoted to the study performed and read the KB tests in batches. The
lead laboratory scientist reread any KB tests with an abnormal result.
The primary objective of this study is to describe the amount of FMH
occurringwith routine D&E from 15weeks 0 days to 23weeks 6 days of
gestation. We aimed to describe preprocedure FMH amounts, the pro-
portion of participants with FMH less than 10 mL and 30 mL of fetal
whole blood inmaternal circulation, and potential associations between
amount of FMH and estimated blood loss, gestational age, procedure
time, fetal anomalies, blood type and Rh status. We also assessed the
proportion of women through 20 weeks 0 days of gestation with FMH
less than 5 mL.
We estimated a convenience sample size based on the assumption
that 100% of samples would demonstrate an FMH of less than 10 mL,
the amount covered by RhIG 100mcg. A sample of 300womenprovided
the lower bounds of a 95% conﬁdence interval of no less than 99%. En-
rollment occurred until 300 pre- and postprocedure specimens were
completed and analyzed. We performed χ2 and Fisher's Exact Tests forcategorical outcomes and Spearman correlations for continuous and
categorical outcomes as appropriate using SAS software version 9.4®
(SAS Institute Inc., Cary, NC, USA). We considered a p value less than
.05 as signiﬁcant.
3. Results
We identiﬁed 386 potential participants during the study period
whomet study inclusion criteria, of whom 61 declined study participa-
tion. Of the 325 enrolled women, 15 discontinued prior to D&E (with-
drew consent or did not complete abortion procedure), 2 had
postprocedure samples which could not be evaluated, and 6 did not
have postprocedure samples. We excluded 2 women who had addi-
tional postprocedure interventions for bleeding, leaving 300 women
in the analysis.
Baseline characteristics of the study population are presented in
Table 1. Notably, about half (51.3%) of the study participants had preg-
nancies at 20 weeks and above (median gestational age 20 weeks
0 days). Preoperative and intraoperative characteristicswhich could po-
tentially affect FMH are presented in Table 2.
Postprocedure phlebotomy for FMH testing occurred at a median of
37min (range 30–112min) after the procedure. Median postprocedure
FMH was 1 mL (range 0–60 mL). Five (1.67%, 95% CI 0.22%–3.12%) par-
ticipants had postprocedure FMH greater than 10 mL (Table 3), two
(0.67%, 95% CI 0%–1.59%) of whom also had postprocedure FMH equal
to or greater than 30 mL. Of those ﬁve participants, two had a gesta-
tional age between 18 and 20 weeks, and three greater than 20 weeks.
None of the 64 women at less than 18 weeks of gestation and none of
the 8 women who received adjunctive mifepristone or misoprostol
had an FMH that exceeded 10 mL.
Table 2
Preoperative and intraoperative characteristics of dilation and evacuation procedures
(N=300)
Characteristic n (%) or median
(range)
Preoperative
Cervical dilator per standard protocol 300 (100%)
Adjunctive mifepristone 4 (1.3%)
Adjunctive misoprostol 4 (1.3%)
Heavy bleeding between cervical preparation and
preprocedure phlebotomy
0
Intraoperative
Heavy bleeding after dilator removal 0
Procedure time (min) 15 (5–51)
Estimated blood loss (mL) 100 (5–2000)
Uterotonic use 42 (14.0)
Complications 20 (6.7%)
Cervical laceration 15
Hemorrhage 5
Table 4
Statistical signiﬁcance between demographic and procedure-related variables and
postprocedure FMH N10 mL in women having a D&E procedure
Variable Number FMH N10 mL p value
Gestational age .59
b18 weeks 64 0
≥18 weeks 236 5 (1.7%)
BMI .51
b30 kg/m2 193 4 (1.3%)
≥30 kg/m2 107 1 (0.3%)
Gravidity .15
1–3 157 3 (1.0%)
4–15 143 2 (0.7%)
Prior vaginal delivery 169 2 (0.7%) .24
Prior cesarean delivery 71 0 .16
Prior miscarriage 76 1 (0.3%) .18
Prior abortion 146 2 (0.7%) .08
Ethnicity .57
Hispanic 77 1 (0.3%)
Non-Hispanic 212 4 (1.3%)
None reported 11 0
Race .25
White 163 4 (1.3%)
Nonwhite 137 1 (0.3%)
Blood type .24
A 102 1 (0.3%)
B 41 1 (0.3%)
AB 5 0
O 152 3 (1.0%)
Rh-status .59
Positive 273 5 (1.7%)
Negative 27 0
Fetal anomaly indication for abortion 39 1 (0.3%) .87
Adjunct cervical preparation
Mifepristone 4 0 .43
Misoprostol 4 0 .13
Estimated blood loss .77
b100 mL 125 2 (0.7%)
≥100 mL 175 3 (1.0%)
Procedure time .87
b15 min 137 2 (0.7%)
≥15 min 163 3 (1.0%)
Uterotonic use 42 0 .37
All data presented as n (%).
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95% CI 2.75%–10.95%) had postprocedure FMH over 5 mL. None of the
24women at less than 16weeks of gestation had an FMH that exceeded
5 mL.
Preprocedure phlebotomy for FMH testing occurred with all speci-
mens obtained within 120 min prior to procedure. Thirty-two (12%,
95% CI 7.17%–14.16%) women had detectable FMH preprocedure with
a median baseline FMH of 0.00 mL (range 0–50 mL). FMH exceeded
5 mL, 10 mL and 30 mL in four (1.33%, 95% CI 0.04%–2.63%), two
(0.67%, 95% CI 0%–1.59%) and one (0.33%, 95% CI 0%–0.99%) partici-
pant(s), respectively (Table 3). The two cases exceeding 10 mL also
had postprocedure FMH N10 mL; neither of these cases had signiﬁcant
vaginal or uterine bleeding noted at cervical dilator placement or
removal.
We found no signiﬁcant associations between demographic charac-
teristics or procedure-related variables and postprocedure FMH
(Table 4).
4. Discussion
We found that the amount of FMH occurring with routine second-
trimester D&E procedures as measured using KB testing is minimal
and adequately covered by RhIG 100 mcg in most cases. Only 12% of
participants had any detectable FMH prior to the procedure. No patients
under 18weeks in our studywould have needed a RhIG dose exceeding
100 mcg. Unexpectedly, 7% of women under 20 weeks of gestation had
postprocedure FMH exceeding 5 mL, which raises concern that the UK
dosing guidelines of RhIG 50 mcg through 20 weeks gestation mayTable 3
Women with FMH exceeding 5 mL by Kleihauer–Betke testing before or after a dilation
and evacuation procedurea
Gestational age Preprocedure FMH (mL) Postprocedure FMH (mL)
19w4d 0.0 5.5
16w4d 0.0 6.5
19w5d 0.0 8.5
19w2d 2.5 5.5
19w5d 5.5 6.0
17w5d 3.0 7.0
19w5d 6.5 7.0
19w3d 2.0 8.5
22w0d 0.0 10.5
18w2d 5.0 12.5
21w1d 19.0 24.0
23w0d 0.0 30.0
19w2d 50.0 60.0
w, weeks; d, days.
a 5mL forwomen15w0d through20w0d; 10mL and30mL forwomen15w0d through
23 w6d.not be adequate in some cases. We found no signiﬁcant relationships
between postprocedure FMH and gestational age, estimated blood
loss, prior pregnancy history, blood type, Rh status or presence of a
fetal anomaly.
Our study provides a unique contribution to our knowledge of
FMH during second-trimester abortion. The only prior study speciﬁ-
cally evaluating FMH with second-trimester abortions included 67
women with fetal anomalies; all but 5 women underwent labor in-
duction abortion [6]. A 1969 study compared “fetal cell scores” in
women having sharp curettage procedures for pregnancy loss or
abortion to controls who did not have a procedure [7]. The authors
presented data based on type of pregnancy loss (threatened versus in-
complete), by treatment method for abortion patients and by gestational
age for the control group (b16 weeks and 16–40 weeks). However, the
authors did not stratify data by gestational age for the pregnancy loss or
abortion groups.
A strength of our study is that we employed a wide range of pro-
viders and learners during the procedures with varying skill levels,
so our ﬁndings are generalizable. We also minimized interreader
variation when reading KB slides by employing only three readers
during the study. We chose not to evaluate preprocedure FMH
prior to cervical preparation; as such, we may have missed any rela-
tionship of the elevated preprocedure FMH evaluations to dilator
placement. Theoretically, dilator placement has the potential to
cause FMH. None of our participants reported any heavy bleeding
after dilator placement, and no physicians reported heavy bleeding
after cervical dilator removal.
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thalassemia and sickle cell disease) that may falsely elevate KB results
due to persistent or high Hgb F levels. Interestingly, two of the ﬁve
women with FMH greater than 10 mL also had detectable baseline
FMH exceeding 10 mL, which could reﬂect an underlying medical con-
dition that affects KB results rather than a result of the procedure itself.
Future studies should screen for hemoglobinopathies or reﬂex test for
hemoglobinopathies if an excessive amount of HgbF cells is found onKB.
Flow cytometry may be a more accurate method of determining
FMH with decreased interuser variation and greater precision once ap-
propriate protocols are set in place. We elected to use KB testing rather
than ﬂow cytometry because KB testing is more generalizable as the
most widespread and accessible quantiﬁcation method in clinical labo-
ratories worldwide [10].
This exploratory study provides a large sample for the quantiﬁcation
of FMH with second-trimester D&E. FMH in routine second-trimester
D&E procedures is small and adequately prophylaxed by RhIG 100
mcg as is used in the UK. The US guideline recommended RhIG 300-
mcg dose is excessive in virtually all cases. Although this study begins
to address the important question of howmuch RhIG is actually needed
for these procedures, it is not large enough to deﬁnitively change cur-
rent practice. Future studies are needed before changing dosing recom-
mendations andmight include a direct comparison of FMHusingKBand
ﬂow cytometry, or evaluation of how much FMH occurs with dilator
placement. Although our ﬁndings also suggest that the UK dosing rec-
ommendations of 50 mcg through 20 weeks may need further assess-
ment, no available data support that women who receive this dose at
16–20 weeks of gestation have higher isoimmunization rates. In time,
reducing the excess amount of RhIG used unnecessarily can help pre-
serve a ﬁnite resource and lower healthcare costs.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.contraception.2018.11.015.Acknowledgments
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